Accuracy and optimal timing of activity measurements in estimating the absorbed dose of radioiodine in the treatment of Graves' disease

被引:24
|
作者
Merrill, S. [1 ]
Horowitz, J. [2 ]
Traino, A. C. [3 ]
Chipkin, S. R. [4 ]
Hollot, C. V. [5 ]
Chait, Y. [1 ]
机构
[1] Univ Massachusetts, Dept Mech & Ind Engn, Amherst, MA 01003 USA
[2] Univ Massachusetts, Dept Math & Stat, Amherst, MA 01003 USA
[3] Azienda Osped Univ Pisana, I-56125 Pisa, Italy
[4] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Amherst, MA 01003 USA
[5] Univ Massachusetts, Dept Elect & Comp Engn, Amherst, MA 01003 USA
基金
美国国家科学基金会;
关键词
THYROID UPTAKE; THERAPY; HYPERTHYROIDISM; KINETICS;
D O I
10.1088/0031-9155/56/3/003
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Calculation of the therapeutic activity of radioiodine I-131 for individualized dosimetry in the treatment of Graves' disease requires an accurate estimate of the thyroid absorbed radiation dose based on a tracer activity administration of I-131. Common approaches (Marinelli-Quimby formula, MIRD algorithm) use, respectively, the effective half-life of radioiodine in the thyroid and the time-integrated activity. Many physicians perform one, two, or at most three tracer dose activity measurements at various times and calculate the required therapeutic activity by ad hoc methods. In this paper, we study the accuracy of estimates of four 'target variables': time-integrated activity coefficient, time of maximum activity, maximum activity, and effective half-life in the gland. Clinical data from 41 patients who underwent I-131 therapy for Graves' disease at the University Hospital in Pisa, Italy, are used for analysis. The radioiodine kinetics are described using a nonlinear mixed-effects model. The distributions of the target variables in the patient population are characterized. Using minimum root mean squared error as the criterion, optimal 1-, 2-, and 3-point sampling schedules are determined for estimation of the target variables, and probabilistic bounds are given for the errors under the optimal times. An algorithm is developed for computing the optimal 1-, 2-, and 3-point sampling schedules for the target variables. This algorithm is implemented in a freely available software tool. Taking into consideration I-131 effective half-life in the thyroid and measurement noise, the optimal 1-point time for time-integrated activity coefficient is a measurement 1 week following the tracer dose. Additional measurements give only a slight improvement in accuracy.
引用
收藏
页码:557 / 571
页数:15
相关论文
共 50 条
  • [1] ACCURACY AND OPTIMAL TIMING OF ACTIVITY MEASUREMENTS IN ESTIMATING ABSORBED DOSE OF RADIOIODINE IN THE TREATMENT OF GRAVES' DISEASE
    Merrill, S.
    Chipkin, S. R.
    Horowitz, J.
    Hollot, C. V.
    Traino, A. C.
    Chait, Y.
    PROCEEDINGS OF THE ASME DYNAMIC SYSTEMS AND CONTROL CONFERENCE 2010, VOL 1, 2010, : 305 - 312
  • [2] The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves' disease
    van Isselt, Johannes W.
    Broekhuizen-de Gast, Henny S.
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2010, 13 (01) : 2 - 5
  • [3] Comparison of Thyroid Size-Specific Radioiodine Dose and New Modified Dose Calculation in the Treatment of Graves' Disease
    Wongsuttilert, Alisara
    Thamcharoen, Ruchirek
    Maiprasert, Yoswanich
    Siriwong, Sathapakorn
    ENDOCRINOLOGY AND METABOLISM, 2024, 39 (05) : 758 - 766
  • [4] Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study
    Howarth, D
    Epstein, M
    Lan, L
    Tan, P
    Booker, J
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (10) : 1489 - 1495
  • [5] Current methods for absorbed dose planning for radioiodine treatment of hyperthyroidism in Sweden
    Jönsson, H
    Mattsson, S
    PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2004, 20 (03): : 99 - 103
  • [6] Outcomes in Relapsed Graves' Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment
    Villagelin, Danilo
    Romaldini, Joao H.
    Santos, Roberto B.
    Milkos, Ana B. B. P.
    Ward, Laura S.
    THYROID, 2015, 25 (12) : 1282 - 1290
  • [7] Radioiodine treatment of pediatric Graves disease: a multicenter review
    Trout, Andrew T.
    Khalatbari, Hedieh
    Shogbesan, Gbenga
    Mirza, Sobia K.
    Sharp, Susan E.
    Alazraki, Adina
    Rostad, Bradley S.
    Parisi, Marguerite T.
    PEDIATRIC RADIOLOGY, 2023, 53 (01) : 21 - 27
  • [8] Radioiodine Therapy for Graves Disease Thyroid Absorbed Dose of 300 Gy-Tuning the Target for Therapy Planning
    Willegaignon, Jose
    Sapienza, Marcelo Tatit
    Buchpiguel, Carlos Alberto
    CLINICAL NUCLEAR MEDICINE, 2013, 38 (04) : 231 - 236
  • [9] Calculating the incalculable. Optimal radioiodine dose in Graves’ hyperthyroidism
    Laszlo Hegedüs
    Steen J. Bonnema
    Endocrine, 2017, 56 : 222 - 223
  • [10] A Systematic Review and Meta-Analysis of the Relationship Between the Radiation Absorbed Dose to the Thyroid and Response in Patients Treated with Radioiodine for Graves' Disease
    Taprogge, Jan
    Gape, Paul M. D.
    Carnegie-Peake, Lily
    Murray, Iain
    Gear, Jonathan, I
    Leek, Francesca
    Hyer, Steve L.
    Flux, Glenn D.
    THYROID, 2021, 31 (12) : 1829 - 1838